NCT05732103 - A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Biotech Hunter

Enrollment

225

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

February 28, 2029

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Interventions

DRUG

CTX-712

CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 once or twice weekly, depending on their dose level assignment, during each 28-day cycle.

Trial Locations (6)

22903

RECRUITING

University of Virginia, Charlottesville

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

55905

RECRUITING

Mayo Clinic Comprehensive Cancer Center, Rochester

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle